Medivir AB: Phase II COSMOS Study Results Published In Lancet On World Hepatitis Day

The phase II COSMOS study evaluated the interferon-free combination of simeprevir and sofosbuvir in treatment-naïve and prior null-responder patients with all stages of liver fibrosis, including cirrhosis.

STOCKHOLM--(BUSINESS WIRE)--Regulatory News:

Medivir AB (OMX: MVIR) announces that results from the phase II COSMOS clinical study were published July 28 in The Lancet, demonstrating that 92 percent of genotype 1 chronic hepatitis C virus adult patients treated with simeprevir in combination with sofosbuvir achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The study included patients with compensated cirrhosis and prior null response to treatment with pegylated interferon and ribavirin.

Help employers find you! Check out all the jobs and post your resume.